Overview

PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of paliperidone extended-release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self).
Phase:
Phase 4
Details
Lead Sponsor:
Janssen Korea, Ltd., Korea
Treatments:
Paliperidone Palmitate